

## Alopecia (Acquired Hair Loss)

### Definition / Supporting Information

Alopecia (hair loss) may be diffuse or partial, scarring or non-scarring, congenital or acquired. Congenital alopecia is described separately.

### Essential History

#### Ask about:

- Onset of hair loss
- Changes in scalp skin such as:
  - Scaling
  - Itch (see Pruritus)
- Physical or emotional stress
- Stress on the hair from:
  - Braiding
  - Teasing
  - Other tightly pulled hairstyles
- Medications such as NSAIDs, sodium valproate\*, amitriptyline hydrochloride, itraconazole, oral contraceptives
- General physical health
- Personal or family history of autoimmune conditions
- Family history of early male pattern hair loss

*\*If prescribing sodium valproate to a young person, be aware of the risks and ensure contraception is being used to protect against becoming pregnant. More information can be found on the Medicines for Children website.*

### 'Red Flag' Symptoms and Signs

#### Ask about:

- Features suggestive of systemic disease
  - Fever
  - Rash
- Recent weight loss
- Behavioural disturbance

### Look for:

- Scarring hair loss.
  - Occurs when the hair follicles are irreparably damaged
  - Hair loss is permanent
    - Atrophic, shiny scalp often with areas of scale around follicles
- Evidence of any of the following associated with the hair loss:
  - Scale
  - Weeping
  - Crusting
  - Pustules
- If any of these are present to a significant extent, consider:
  - Tinea capitis or
  - Kerion

## Differential Diagnosis / Conditions

### Diffuse non-scarring alopecia

- Telogen effluvium
  - Occurs a few months after an illness, surgery or stressful event
  - Hairs go simultaneously into resting phase and are shed together analogous to moulting in animals
    - Regrowth occurs over a few months
- General ill health and nutritional deficiency
  - Chronic inflammatory conditions can be associated with hair thinning
  - Consider anaemia and iron deficiency
  - Rarely trace element deficiency can cause hair thinning
    - Acrodermatitis enteropathica
    - Malabsorption
- Endocrine disorders
  - Hyperthyroidism
  - Hypothyroidism
  - Hypopituitarism
  - Male pattern (androgenetic) hair loss
    - Occurs in both sexes
    - Thinner at the vertex and temples
    - Consider underlying endocrine abnormality (eg, polycystic ovary in girls if severe and onset unusually early)

## Localised non-scarring alopecia

- Alopecia areata
  - Most often an acute problem
    - Sharply demarcated, round, nearly bald patches
    - Stubby exclamation mark hairs
  - Patches tend to be several centimetres in diameter
    - Usually on the scalp
  - Prognosis depends on rate and extent of hair loss
  - Prognosis is worst in patients with:
    - Rapid total scalp hair loss (alopecia totalis)
    - Total body hair loss (alopecia universalis)



Figure 1: Alopecia areata

- Traction alopecia
  - Tight ponytails or braids causing chronic traction cause patchy hair loss
    - Can eventually develop into scarring alopecia
- Trichotillomania
  - Irregularly shaped areas of thinned stubble of varying lengths
    - Large, patchy, ill-defined patterns
    - Area of hair loss is most accessible to the probing hand
    - May simulate alopecia areata

- Some children have a compulsive need to pull out their hair or even eyebrows or eyelashes
- Patient may eat hair, which can accumulate in the stomach and form a trichobezoar (hairball)
- May sometimes (but not always) provide a major clue to an underlying psychosocial problem



Figure 2: Trichotillomania

- Traumatic alopecia

**Scarring alopecia (may be non-scarring initially)**

- Tinea capitis and kerion
  - Tinea capitis
    - Mild: Round, minimally inflamed alopecic area with slight seborrhoeic scale or stubby hair growth (non-scarring)
    - Severe: Boggy, tender often pustular, severely inflamed kerion
    - Kerion lesions tend to be:
      - More elevated than in other forms of tinea capitis
      - Characterised by black dots
    - Local adenopathy may be present (see Lymphadenopathy)

- Differential diagnosis includes:
  - Seborrhoeic dermatitis
  - Atopic dermatitis
  - Psoriasis
  - Bacterial infection



Figure 3: Tinea capitis

- Kerion
  - Delayed hypersensitivity reaction to fungus
  - If unchecked, resultant scarring interferes with the regrowth of hair
  - Early diagnosis and treatment are therefore helpful



Figure 4: Kerion secondary to chronic progressive Tinea capitis

- Inflammatory skin diseases
  - Discoid lupus erythematosus
  - Lichen planus
  - Localised scleroderma (en coup de sabre morphoea)

## Investigations

To be undertaken by non-specialist practitioners (eg, General Practitioner (GP) Team, usually with specialist advice), or specialist practitioners (eg, Emergency Department / Paediatric / Paediatric Dermatology Team(s)):

- Features suggesting significant underlying illness include:
  - Weight loss
  - Other systemic features
  - Failure of telogen effluvium to resolve
- These warrant further investigations including:
  - Full blood count and haematinic studies

- Inflammatory markers (eg, C-reactive protein)
- Urea, electrolyte and liver function tests
- Thyroid function
- Antinuclear antibodies
- Radiography (if indicated):
  - Trichotillomania
    - Presence of a trichobezoar
- Scrapings and hair pluckings for mycology if tinea capitis suspected

To be undertaken by specialist practitioners (eg, Paediatric Dermatology Team):

- Biopsy
  - Miniaturised anagen bulbs in androgenetic alopecia

## Treatment Approach

Treatment depends on the underlying cause of alopecia.

To be undertaken by non-specialist practitioners (eg, GP Team, usually with specialist advice), or specialist practitioners (eg, Emergency Department / Paediatric / Paediatric Dermatology Team(s)):

- Treat iron deficiency if identified

### Alopecia areata

- Treatment is of limited long-term benefit and may cause significant side-effects such as skin atrophy. Consider no treatment.
- Potent or very potent topical steroid
- Irritants or topical immunomodulators (specialist (Paediatric Dermatology Team) use only)
  - Used for extensive alopecia
  - Dinitrochlorobenzene immunotherapy
  - Psoralen with ultraviolet A light (PUVA therapy)

### Trichotillomania

- Treatments unlikely to be successful if underlying emotional issue is not addressed
- Petroleum jelly may be applied to affected areas to deter pulling
- Imipramine hydrochloride (note that hair loss is also a potential adverse effect)
- Fluoxetine
- Surgery or endoscopy
  - Referral for removal of a trichobezoar

### Tinea capitis

- Oral terbinafine (unlicensed but Children's BNF gives specific dose ranges for tinea capitis)

### **Lupus erythematosus**

- Discoid variant
  - Early treatment with topical or intralesional steroids may prevent scarring
- Systemic variant
  - Loss of hair is generally temporary

### **Acrodermatitis enteropathica**

- Oral zinc sulfate is the treatment of choice

### **Strategies for the patient to hide noticeable loss of hair:**

- Psychological coping strategies
  - Consider referral to a service such as “Changing Faces” (available nationally)
- Headwear
- Plastic surgery
  - Expertise should be sought for consideration of hair transplants and scalp reduction (for scarred areas) when possible

## **When to Refer**

Refer urgently to specialist practitioners (eg, Emergency Department / Paediatric / Paediatric Dermatology Team(s)) if:

- Features suggestive of systemic disease
  - Fever
  - Rash
- Recent weight loss

Escalate care to Paediatric Dermatology Team if:

- Rapid, diffuse hair loss
- Chronic, progressive, localised, or diffuse hair loss without regrowth
- Scarring alopecia
- Inability to grow hair as a result of:
  - Breakage
  - Loss
  - Abnormal texture of hair
- Appearance of scalp mass or plaque affecting localised hair loss
- Hair loss is causing significant psychological distress

Consider referral to Mental Health Services if emotional stress is believed to be underlying cause (eg, trichotillomania).

## ‘Safety Netting’ Advice

Advise families to seek further medical advice if:

- ‘Red flag’ signs or symptoms develop
- No improvement after 3 months
- Side-effects of terbinafine
- Provide advice on the use of sunblock and / or a hat to protect hair loss patches from sun damage

## Patient / Carer Information

***\*Please note: whilst these resources have been developed to a high standard they may not be specific to children.***

- [Alopecia areata](#) (Web page), British Association of Dermatologists
- [Children and young people](#) (Web page), Alopecia UK
- [Hair Loss](#) (Web page), the NHS website
- [Trichotillomania](#) (Web page), the NHS website

## Resources

### National Clinical Guidance

[Guidelines for the management of alopecia areata](#) (PDF), British Association of Dermatologists

[Alopecia areata](#) (Web page), National Institute for Health and Care Excellence Clinical Knowledge Summary

### Medical Decision Support

Lewis-Jones S, ed. Oxford Handbook of Paediatric Dermatology Oxford: Oxford University Press, 2010.

## Suggested Resources

***\*Please note: these resources include links to external websites. These resources may not have national accreditation and therefore PCO UK cannot guarantee the accuracy of the content.***

[Alopecia Areata](#), NICE clinical knowledge summary, National Institute for Health and Care Excellence.

Atton A, Tunnessen W. Alopecia in children: the most common causes. *Pediatr Rev* 1990;12:25–30. [[PubMed](#)]

Harrison S, Sinclair R. Optimal Management of Hair Loss (Alopecia) in Children. *American Journal of Clinical Dermatology* 2003;4: 757–70 [[PubMed](#)]

Price VH. Androgenetic alopecia in adolescents. *Cutis* 2003;71:115–121 [[PubMed](#)]

Roberts BJ, Friedlander SF. Tinea capitis: a treatment update. *Pediatr Ann* 2005;34:191–200 [[PubMed](#)]

## Acknowledgements

**Content Editor:** Dr Doug Simkiss

**Clinical Expert Reviewers:** Dr Lindsay Shaw and Dr Lea Solman

**GP Reviewer:** Dr Ian A Dunn

**AAP Reviewer:** Jane Meschan Foy, MD, FAAP

**Paediatric Trainee Reviewer:** Dr Orode Omawunmi Ogun

**Update Reviewer:** Dr Surya Dhulipala (trainee paediatrician)

**Paediatric Specialty Group:** [British Society for Paediatric Dermatology](#)

### Update information

Created: 2017

Date last updated: 2019

Next review due: 2022